Cargando…

PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation

Reducing the incidence of graft-versus-host disease (GVHD) after haploidentical hematopoietic stem cell transplantation (HSCT) is warranted. Posttransplant cyclophosphamide (PTCy) is the main agent used for GVHD prevention in this setting. It remains unknown whether costimulation blockade can be saf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Homsi, A. Samer, Cirrone, Frank, Wo, Stephanie, Cole, Kelli, Suarez-Londono, J. Andres, Gardner, Sharon L., Hsu, Jingmei, Stocker, Kelsey, Bruno, Benedetto, Goldberg, Judith D., Levinson, Benjamin A., Abdul-Hay, Maher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368845/ https://www.ncbi.nlm.nih.gov/pubmed/37163349 http://dx.doi.org/10.1182/bloodadvances.2023010545

Ejemplares similares

Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure
por: Stenger, Elizabeth O., et al.
Publicado: (2023)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Allodepleted T‐cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft‐versus‐host disease (GVHD) in the absence of GVHD prophylaxis
por: Roy, Denis Claude, et al.
Publicado: (2019)

Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation
por: Williams, Louis, et al.
Publicado: (2020)

Higher graft cell dose does not influence development of acute or chronic GVHD in haploidentical transplantation using PTCy
por: Nawas, Mariam T., et al.
Publicado: (2023)

HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age
por: Ambinder, Alexander, et al.
Publicado: (2022)

GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT
por: Baron, Frédéric, et al.
Publicado: (2023)

Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy
por: Zou, Jun, et al.
Publicado: (2022)

Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes
por: Herzog, Shannon, et al.
Publicado: (2023)

Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium
por: DeFilipp, Zachariah, et al.
Publicado: (2021)

Donor bone marrow–derived macrophage MHC II drives neuroinflammation and altered behavior during chronic GVHD in mice
por: Adams, Rachael C., et al.
Publicado: (2022)

Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning
por: Wagner, John E., et al.
Publicado: (2021)

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
por: Akahoshi, Yu, et al.
Publicado: (2023)

Haploidentical haematopoietic stem cell transplantation for thalassaemia major based on an FBCA conditioning regimen
por: Sun, Qixin, et al.
Publicado: (2018)

Third-party type 2 innate lymphoid cells prevent and treat GI tract GvHD
por: Bruce, Danny W., et al.
Publicado: (2021)

Role of NKG2D ligands and receptor in haploidentical related donor hematopoietic cell transplantation
por: Petersdorf, Effie W., et al.
Publicado: (2023)

Selected memory T cells infused post–haploidentical hematopoietic stem cell transplantation persist and hyperexpand
por: van Beek, Jasper J. P., et al.
Publicado: (2022)

Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse
por: Shapiro, Roman M., et al.
Publicado: (2023)

Improved access to HCT with reduced racial disparities through integration with leukemia care and haploidentical donors
por: Bashey, Asad, et al.
Publicado: (2023)

Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults
por: Vasu, Sumithira, et al.
Publicado: (2022)

ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD
por: Xiao, Zunyu, et al.
Publicado: (2022)

Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation
por: Ueda Oshima, Masumi, et al.
Publicado: (2023)

Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning
por: Iwasaki, Makoto, et al.
Publicado: (2022)

The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation
por: Metafuni, Elisabetta, et al.
Publicado: (2022)

MicroRNA-31 regulates T-cell metabolism via HIF1α and promotes chronic GVHD pathogenesis in mice
por: Wu, Yongxia, et al.
Publicado: (2022)

A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis
por: Yu, Xiaoliang, et al.
Publicado: (2023)

Mesenchymal stromal cells ameliorate chronic GVHD by boosting thymic regeneration in a CCR9-dependent manner in mice
por: Zhang, Xin, et al.
Publicado: (2023)

Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type
por: Mehta, Rohtesh S., et al.
Publicado: (2023)

Current Status and Future Directions in Graft-Versus-Host Disease Prevention Following Allogeneic Blood and Marrow Transplantation in Adults
por: Tegla, Cosmin, et al.
Publicado: (2020)

Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppression
por: Nakamura, Makoto, et al.
Publicado: (2021)

Single-cell immune profiling reveals a developmentally distinct CD4(+) GM-CSF(+) T-cell lineage that induces GI tract GVHD
por: Piper, Clint, et al.
Publicado: (2022)

Human Herpes Virus-6 Encephalitis Following Autologous Blood and Marrow Transplant
por: Azzi, Jacques Mario, et al.
Publicado: (2019)

Does the Tacrolimus Trough Level Adequately Predict Drug Exposure in Patients Requiring a High Tacrolimus Dose?
por: Haverals, Lien, et al.
Publicado: (2023)

Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies
por: Li, Hua, et al.
Publicado: (2021)

Tacrolimus-Induced Optic Neuropathy After Multivisceral Transplantation
por: Canovai, Emilio, et al.
Publicado: (2019)

Clinical Outcomes Using Mycophenolate and Tacrolimus for Graft-versus-Host Disease Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplant: A Single Institution Experience
por: Hashmi, Hamza, et al.
Publicado: (2020)

The Association of Tacrolimus Formulation on Cerebral Blood Flow and Cognitive Function
por: Mahaparn, Irisa, et al.
Publicado: (2023)

Efficacy of Prolonged-release Tacrolimus After Conversion From Immediate-release Tacrolimus in Kidney Transplantation: A Retrospective Analysis of Long-term Outcomes From the ADMIRAD Study
por: Kuypers, Dirk, et al.
Publicado: (2023)

Tacrolimus-Induced Hyponatremia in Lung Transplant Recipients: A Case Series
por: Banks, Paul N., et al.
Publicado: (2018)

NK cells produce high levels of IL‐10 early after allogeneic stem cell transplantation and suppress development of acute GVHD
por: Chan, Yuen Ling Tracey, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7jaanng20g0or18naqigal1vdk